Provention Bio

Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Tue, 06/13/23 - 11:37 am
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Pfizer's fortunes overshadow first-quarter dealmaking
EP Vantage
Wed, 04/12/23 - 10:22 am
M&A
Pfizer
Seagen
Sanofi
Provention Bio
AstraZeneca
CinCor
Chiesi
Amryt
Ipsen
Albireo
Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?
Fierce Pharma
Tue, 04/11/23 - 11:46 am
M&A
antitrust
FTC
Sanofi
Provention Bio
Pfizer
Seagen
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Fierce Pharma
Mon, 03/13/23 - 10:08 am
Sanofi
Provention Bio
M&A
diabetes
Delaying type 1 diabetes progression: major trial readouts to watch in 2023
Clinical Trials Arena
Mon, 02/20/23 - 12:54 pm
clinical trials
type 1 diabetes
Provention Bio
Tzeild
Diamyd Medical
remygen
Imcyse
IMCY-0098
ProKidney
FDA greenlights Provention Bio's diabetes drug
Yahoo/Reuters
Fri, 11/18/22 - 10:22 am
Provention Bio
type 1 diabetes
FDA
teplizumab
Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug
BioSpace
Thu, 10/6/22 - 07:07 pm
Provention Bio
Sanofi
type 1 diabetes
teplizumab
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Provention’s embattled diabetes med delayed again by FDA to consider new info
Fierce Biotech
Thu, 06/30/22 - 10:15 pm
Provention Bio
teplizumab
FDA
diabetes
FDA sets August decision date for Provention’s type 1 diabetes drug
Pharmaforum
Mon, 03/21/22 - 10:15 am
Provention Bio
type 1 diabetes
FDA
teplizumab
Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks
Fierce Biotech
Mon, 09/13/21 - 10:38 am
Provention Bio
type 1 diabetes
FDA
teplizumab
Big pharma leads the way in stock market resurgence
EP Vantage
Wed, 07/7/21 - 10:49 am
Big Pharma
pharma stocks
Acadia Pharmaceuticals
AstraZeneca
Biogen
Eli Lilly
GSK
Merck
Moderna Therapeutics
Novartis
Sanofi
Provention Bio
Provention Bio slapped with FDA rejection for diabetes hopeful teplizumab
Fierce Biotech
Tue, 07/6/21 - 10:58 am
Provention Bio
FDA
teplizumab
type 1 diabetes
complete response letter
FDA Action Alert: Vericel and Provention Bio
BioSpace
Mon, 06/28/21 - 06:51 pm
Vericel
NexoBrid
Provention Bio
teplizumab
type 1 diabetes
FDA
FDA adcomm votes in favor of approving Provention Bio’s drug to delay type 1 diabetes
Endpoints
Thu, 05/27/21 - 11:57 pm
Provention Bio
FDA
teplizumab
type 1 diabetes
Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs to satisfy the FDA
Fierce Biotech
Tue, 05/25/21 - 11:52 pm
Provention Bio
FDA
advisory panels
diabetes
teplizumab
Provention warns FDA requests could delay diabetes approval
Fierce Biotech
Fri, 04/9/21 - 10:46 am
Provention Bio
FDA
teplizumab
type 1 diabetes
Provention Bio gives update on teplizumab BLA, FDA feedback
Seeking Alpha
Thu, 04/8/21 - 07:34 pm
Provention Bio
FDA
teplizumab
type 1 diabetes
After midstage flop, Janssen says thanks but no thanks to Provention Bio drug
Fierce Biotech
Fri, 01/3/20 - 10:02 am
Janssen
Provention Bio
Crohn’s disease
PRV-6527
JNJ

Pages